Endothelial dysfunction and risk factors for atherosclerosis in psoriatic arthritis: overview and comparison with rheumatoid arthritis
Rheumatol Int. 2024 Mar 24. doi: 10.1007/s00296-024-05556-x. Online ahead of print.ABSTRACTEndothelial dysfunction (ED) is defined as an impairment in the vasodilatory, anti-thrombotic, and anti-inflammatory properties of the cells that make up the lining of blood vessels. ED is considered a key step in the development of atherosclerotic cardiovascular disease. The association between ED and systemic inflammatory diseases is well established. However, the prevalence and clinical significance of ED in psoriatic arthritis (PsA) have been investigated to a lesser extent. This review aims to explore the link between ED and PsA...
Source: Atherosclerosis - March 24, 2024 Category: Cardiology Authors: Konrad Kaleta Julia Krupa Wiktoria Suchy Anna Sopel Mariusz Korkosz Jaros ław Nowakowski Source Type: research
Case report: Tofacitinib alleviates psoriatic arthritis without exacerbating multiple sclerosis
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 23, 2024 Category: Rheumatology Authors: Yaran Yang,
Wei Zhou Tags: LETTER TO THE EDITOR Source Type: research
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
AbstractAs of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic. Most studies evaluated infliximab, while a smaller number evaluated adalimumab, rituximab or etanercept. Indications studied now include sarcoidosis, as well as the indications previously reported of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis and inflammatory bowel disease (Crohn ’s disease and ulcerative colitis). This updated data set includes eight additional studi...
Source: BioDrugs - March 23, 2024 Category: Drugs & Pharmacology Source Type: research
The Psoriasis Treatment Pipeline
Significant research advances in our understanding of psoriatic disease have led to the development of several highly selective, effective, and safe topical and systemic treatments. These treatments have led to unprecedented levels of disease clearance and control for most patients with psoriasis with cutaneous disease. However, there remains a need for improved treatments for those patients with recalcitrant disease, psoriatic arthritis, or nonplaque disease variants. Recently approved therapies and investigational products in ongoing clinical development programs that target IL-17A/F, IL-23, TYK2, PDE4, AhR or IL-36 cyto...
Source: Dermatologic Clinics - March 23, 2024 Category: Dermatology Authors: Jason E. Hawkes, Miriam Al-Saedy, Nicole Bouch é, Salsabeal Al-Saedy, Delaney T. Drew, Eingun James Song Source Type: research
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
AbstractAs of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic. Most studies evaluated infliximab, while a smaller number evaluated adalimumab, rituximab or etanercept. Indications studied now include sarcoidosis, as well as the indications previously reported of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis and inflammatory bowel disease (Crohn ’s disease and ulcerative colitis). This updated data set includes eight additional studi...
Source: BioDrugs - March 23, 2024 Category: Drugs & Pharmacology Source Type: research
Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis
CONCLUSIONS: In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.PROTOCOL REGISTRATION: PROSPERO: CRD42022315577.PMID:38515177 | DOI:10.1186/s42358-024-00361-3 (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Thais Montezuma Livia Fernandes Probst Matheus Oliveira Almeida Source Type: research
Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis
CONCLUSIONS: In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.PROTOCOL REGISTRATION: PROSPERO: CRD42022315577.PMID:38515177 | DOI:10.1186/s42358-024-00361-3 (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Thais Montezuma Livia Fernandes Probst Matheus Oliveira Almeida Source Type: research
Synovial 5 ‐LOX‐derived oxylipins define a lympho‐myeloid‐enriched synovium
ConclusionThe lack of correlation between ST and plasma oxylipins suggests that synovial tissue lipid profiling better characterizes active pathways in treated joints. Synovial 5-LOX-derived oxylipins were highly expressed in lympho-myeloid-enriched synovium. Combination therapy with 5-LOX inhibitors to improve refractory inflammation may be needed in patients with this histological group. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - March 21, 2024 Category: Rheumatology Authors: Jessica D. Murillo ‐Saich,
Roxana Coras,
Julio Ramirez,
Estefania Quesada‐Masachs,
Marta Sala‐Climent,
Katharina Eschelbach,
Christopher B Mahony,
Raquel Celis,
Aaron Armando,
Oswald Quehenberger,
Adam P Croft,
Arthur Kavanaugh,
Eric Cha Tags: Full Length Source Type: research
From Psoriasis to Psoriatic Arthritis: Ultrasound Insights Connecting Psoriasis with Subclinical Musculoskeletal Inflammation and the Path to Psoriatic Arthritis
AbstractPurpose of ReviewThis review summarizes the literature about the transition from psoriasis to psoriatic arthritis (PsA), focusing on musculoskeletal ultrasound (MSUS) for detecting subclinical inflammation and its role in diagnosis and triage of high-risk patients.Recent FindingsMSUS effectively detects subclinical musculoskeletal inflammation in patients with psoriasis; however, some of these lesions are non-specific and can be found in healthy individuals. Preliminary evidence suggest that subclinical sonographic findings may predict progression to PsA in psoriasis patients. MSUS can also improve referrals ’ ac...
Source: Current Rheumatology Reports - March 21, 2024 Category: Rheumatology Source Type: research
Synovial 5 ‐LOX‐derived oxylipins define a lympho‐myeloid‐enriched synovium
ConclusionThe lack of correlation between ST and plasma oxylipins suggests that synovial tissue lipid profiling better characterizes active pathways in treated joints. Synovial 5-LOX-derived oxylipins were highly expressed in lympho-myeloid-enriched synovium. Combination therapy with 5-LOX inhibitors to improve refractory inflammation may be needed in patients with this histological group. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - March 20, 2024 Category: Rheumatology Authors: Jessica D. Murillo ‐Saich,
Roxana Coras,
Julio Ramirez,
Estefania Quesada‐Masachs,
Marta Sala‐Climent,
Katharina Eschelbach,
Christopher B Mahony,
Raquel Celis,
Aaron Armando,
Oswald Quehenberger,
Adam P Croft,
Arthur Kavanaugh,
Eric Cha Tags: Full Length Source Type: research
Gastrointestinal histoplasmosis with small intestinal perforation: 20-year experience
AbstractPostmortem studies show gastrointestinal tract involvement in as many as 70% of patients affected by disseminated histoplasmosis. Although gastrointestinal involvement is common in disseminated disease, the presentation of small intestinal perforation is exceedingly rare with few reported cases in the literature. Herein we present our institutional case series. The aim of the study is to describe small intestinal perforation in gastrointestinal histoplasmosis with attention to management and outcomes. This is a retrospective single-institution review of patients ≥ 18 years of age treated for small intestina...
Source: Updates in Surgery - March 20, 2024 Category: Surgery Source Type: research
scDrugPrio: a framework for the analysis of single-cell transcriptomics to address multiple problems in precision medicine in immune-mediated inflammatory diseases
ConclusionsWe propose a computational framework, scDrugPrio, for drug prioritisation based on scRNA-seq of IMID disease. Application to individual patients indicates scDrugPrio ’s potential for personalised network-based drug screening on cellulome-, genome-, and drugome-wide scales. For this purpose, we made scDrugPrio into an easy-to-use R package (https://github.com/SDTC-CPMed/scDrugPrio). (Source: Genome Medicine)
Source: Genome Medicine - March 20, 2024 Category: Genetics & Stem Cells Source Type: research
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis
CONCLUSION: The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.PMID:38503473 | DOI:10.1136/ard-2024-225534 (Source: Herpes)
Source: Herpes - March 19, 2024 Category: Infectious Diseases Authors: Andreas Kerschbaumer Josef S Smolen Ricardo J O Ferreira Heidi Bertheussen Xenofon Baraliakos Daniel Aletaha Dennis G McGonagle D ésirée van der Heijde Iain B McInnes Bente Appel Esbensen Kevin L Winthrop Wolf-Henning Boehncke Jan W Schoones Laure Gosse Source Type: research
Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors
In this report, we w ill discuss the importance of considering paradoxical colitis in the differential diagnosis for patients even several years after TNF-α/IL-17 inhibitor initiation and explain why careful consideration must be made when initiating these colitis-inducing agents to treat patients with inflammatory dis orders. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - March 19, 2024 Category: Gastroenterology Source Type: research
